Help patients
seeking
weight loss
control
their
cravings

Not an actual patient.

Consider Mysimba® for your patients seeking weight loss who struggle with emotional eating1

Mysimba® is a MHRA and EMA approved, nonstimulant, oral weight-loss medication to be used as an adjunct to a reduced-calorie diet and increased physical activity for adults with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).2

Mysimba® is designed to reduce hunger and control cravings, so your patients can lose weight and keep it off.2,3†

The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.2

BMI=body mass index.

Emotional eating—a challenge for weight-loss success

When it comes to treating obesity, one size doesn’t fit all. Every patient is different, and their treatment should be too. The Acosta et al observational study found that an individualized treatment approach based on 4 obesity-related phenotypes was associated with significantly greater weight loss after 12 months compared with the non–phenotype-guided groups. For some patients, this means addressing their cravings that can be associated with emotional eating, which occurs when someone eats to cope with positive or negative emotions.1

Proven efficacy with Mysimba®

Help your patients who are overweight or struggling with obesity achieve sustained weight loss.2,4

On average, completers achieved 11.5% weight loss vs 7.3% for placebo at 56 weeks4‡

ITT-LOCF: -8.1% for Mysimba® and -4.9% for placebo2‡

Image of purple scale which shows the average weight loss experienced with Mysimba® (naltrexone HCl/bupropion HCl) prescription pills

Completers lost an average of 11.3 kg vs 7.3 kg for placebo at 56 weeks4‡

ITT-LOCF: ~8.2 kg for Mysimba® and ~5.0 kg for placebo2‡

Measure your progress from Mysimba® (naltrexone HCl/bupropion HCl) Weight Loss Pills with Purple Tape Measure

There was an average decrease of 11.2 cm in waist circumference for completers vs 7.6 cm for placebo5‡

ITT-LOCF: -11.2 cm for Mysimba® and -7.6 cm for placebo2‡

Mysimba® targets 2 areas of the brain to reduce hunger and control cravings2,3§

Mysimba® is the only MHRA and EMA-approved, 2-in-1 combination drug containing prolonged-release (PR) naltrexone and bupropion that targets the brain’s appetite regulatory center and the mesolimbic reward system.2

Authentic Mysimba®

§The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.2

Layers Mysimba® (naltrexone HCl/bupropion HCl) weight loss pills target with bupropion SR, inner layer, and naltrexone SR
A bag of stress labeled chips on a kitchen counter for emotional eating

Do your patients seeking weight loss eat for comfort?

Find out more about the obstacles patients may face when trying to lose weight, and identify which of your patients may be right for Mysimba®.

A bag of stress labeled chips on a kitchen counter for emotional eating
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References:

  1. Acosta A, Camilleri M, Dayyeh BA, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662-671. doi:10.1002/oby.23120
  2. Mysimba® (naltrexone HCl and bupropion HCl) Summary of Product Characteristics (SmPC).
  3. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-1196. doi:10.1038/ijo.2015.59
  4. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120. doi:10.1038/oby.2010.147
  5. Data on file (Waist Circumference).
  6. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4